Weekly Policy Blog: CBSA Advocates for Medicare Coverage of Emerging Technologies
CBSA advocates for policies that improve patient access to critical life-saving novel technologies. The bipartisan Ensuring Patient Access to Critical Breakthrough Products Act of 2023 (H.R. 1691), which was introduced by Reps. Brad Wenstrup (R-OH) and Suzan DelBene (D-WA) on March 31st, has garnered growing support with 50 co-sponsors. CBSA applauds Colorado U.S. Representative Diana DeGette for signing-on as the most recent co-sponsor of H.R. 1691. This House bill seeks to provide four years of Medicare coverage for medical devices that receive approval from the FDA under the Breakthrough Devices Program. It would also create a roadmap for additional data collection for CMS to make a permanent coverage decision after the initial four years.
This week, CMS also released its notice on the long-awaited proposed Transitional Coverage for Emerging Technologies (TCET) pathway, which is an…
Click here to view original post
